Taking stock of the drug industry, from the lab to the medicine chestJune 5, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | To push antibiotic makers to be more green, a new system will certify manufacturing practices An industry group is launching a new system to certify that antibiotic drug manufacturers meet environmental goals. By Ed Silverman STAT+ | Ted Love, BIO's first Black board chair, aims to rehab biotech's image in Washington Ted Love hopes to use his experience across drug development to improve the biotech industry's reputation following a bruising lobbying fight By Rachel Cohrs STAT+ | Gilead's CAR-T therapy prolongs survival in key blood cancer trial Yescarta is the first CAR-T to show longer survival for this blood cancer in a randomized study, another milestone for the therapy. By Adam Feuerstein ADOBE, Alex Hogan/STAT STAT+ | Bellerophon Therapeutics trial fails despite innovative digital endpoint Bellerophon is abandoning a Phase 3 trial of its pulmonary fibrosis treatment after patients using a digital endpoint showed no improvement. By Mario Aguilar Akero's NASH drug combined with Ozempic cut liver fat in small study In a small study, patients taking Akero's NASH drug with a GLP-1 like Ozempic had reduced liver fat and improved markers of liver scarring. By Elaine Chen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments